Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
9 min read
Iparomlimab/Tuvonralimab in Mismatch repair-deficient Endometrial Carcinoma: NCT07369986 Clinical Landscape Report 2026
18 September 2026
NCT07369986 clinical landscape for Mismatch repair-deficient Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and develop…
9 min read
Everolimus in Hepatocellular Carcinoma: NCT07369505 Clinical Landscape Report 2026
18 September 2026
NCT07369505 clinical landscape for Hepatocellular Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Iparomlimab/Tuvonralimab in Triple Negative Breast Cancer: NCT07372079 Clinical Landscape Report 2026
18 September 2026
NCT07372079 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Oliceridine fumarate in Anesthesia: NCT07372209 Clinical Landscape Report 2026
18 September 2026
NCT07372209 clinical landscape for Anesthesia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CMG1A46 in Sjogren's Syndrome: NCT07371468 Clinical Landscape Report 2026
18 September 2026
NCT07371468 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Benmelstobart in Endometrial Carcinoma: NCT07371663 Clinical Landscape Report 2026
18 September 2026
NCT07371663 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Enzalutamide in Breast Cancer: CTRI/2026/01/102272 Clinical Landscape Report 2026
18 September 2026
CTRI/2026/01/102272 clinical landscape for Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Albumin-Bound Paclitaxel in Triple Negative Breast Cancer: NCT07376629 Clinical Landscape Report 2026
18 September 2026
NCT07376629 clinical landscape for Triple Negative Breast Cancer: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Genakumab in Systemic Lupus Erythematosus: NCT07381465 Clinical Landscape Report 2026
18 September 2026
NCT07381465 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
Toripalimab in Muscular Dystrophy, Facioscapulohumeral: NCT07378306 Clinical Landscape Report 2026
18 September 2026
NCT07378306 clinical landscape for Muscular Dystrophy, Facioscapulohumeral: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
9 min read
TH027 CAR-T Cells(ThinkingBiomed) in Glioblastoma: NCT07384390 Clinical Landscape Report 2026
18 September 2026
NCT07384390 clinical landscape for Glioblastoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
9 min read
CGT-6297 in Endometrial Carcinoma: NCT07383506 Clinical Landscape Report 2026
18 September 2026
NCT07383506 clinical landscape for Endometrial Carcinoma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.